论文部分内容阅读
美国FDA批准了一种新型吸入性复方支气管扩张剂,用以长期维持治疗慢性阻塞性肺疾病患者的气道阻塞症状。诺华公司的Utibron Neohaler,含有长效β2-肾上腺素受体激动剂茚达特罗(27.5 ug)和长效毒蕈碱受体拮抗剂格隆溴铵
The U.S. FDA approved a new inhaled compound bronchodilator to maintain long-term maintenance of airway obstruction in patients with chronic obstructive pulmonary disease. Novartis’s Utibron Neohaler, which contains the long-acting β2-adrenergic receptor indacaterol (27.5 ug) and the long-acting muscarinic receptor antagonist glycopyrrolate